HeyJaredMelissa Fleming
- Indexed articles, last 90 days
- 6
- Latest publication
- Jul 29, 2026
- Outlet visibility, for MM+M - Medical Marketing and Media
- Top 5M sites
- Earliest in this view
- Jul 7, 2026
Latest articles
Rewriting the rules of B2B engagement (opens the original)
Read excerpt
B2B healthcare engagement is at an inflection point. Precision targeting and information delivery is being reshaped by changing expectations, evolving platforms and a more complex, human decision-making landscape. Today’s healthcare professionals (HCPs) aren’t just passive recipients of content, they’re active participants in dynamic, digital ecosystems where relevance, credibility and context matter more than ever. Yet, many brands still rely on outdated models of engagement: overly transaction
Building a creative-first marketing culture in pharma (opens the original)
Read excerpt
PANELISTS– Denise Dalton, founder and CEO, Dalton Life Sciences Solutions– Mike Rosich, CEO, Current Group– Burcak Simsek, global strategy lead, Bayer Pharmaceuticals– Moderator: Jameson Fleming, editorial director, MM+M The legacy playbook of pharma marketing prioritized clinical data over human connection. For decades, brand teams launched campaigns anchored in safety profiles, molecular structures and clinical efficacy. However, as medical congresses grow more crowded and consumer media habit
Creative that works harder, a conversation at Cannes (opens the original)
Read excerpt
– Richard Case, VP of growth marketing, GoodRx– Kimberly Francella-Faver, SVP, brand partnerships, NBCUniversal Advertising and Partnerships– Resh Sidhu, VP and head of creative, Adobe– Moderator: Jameson Fleming, editorial director, MM+M “Eighty percent of success is showing up” may be true for some things — such as scoring bar seats at a restaurant or finding sand dollars at the beach — but that adage doesn’t apply to marketing. In a hyper-fragmented media landscape, brands need creative with
As oncology competition intensifies, differentiation moves upstream (opens the original)
Read excerpt
With more therapies, more data and growing momentum behind combination treatments, oncology companies are facing unprecedented pressure to differentiate. In today’s increasingly competitive landscape, defining what makes an asset unique can no longer be treated as a late-stage commercialization exercise. Historically, clinical and creative pathways have traditionally functioned independently, with commercial teams developing positioning, naming and brand identity late in the product lifecycle. T
Life sciences marketers: Your plan is wrong (opens the original)
Read excerpt
PANELISTS– Craig Haines, chief revenue officer, People Inc.– Eric Lloyd, chief revenue officer, IQVIA Digital– Andrea Palmer, CEO, Publicis Health Media– Megan Suttile, associate VP of global media & partnerships, Eli Lilly & Company-Moderator: Steve Madden, editor at large, MM+M For decades, life sciences marketing has been planned and executed as if healthcare professionals (HCPs) and patients occupy separate universes with distinct audiences, different channels and parallel strategies. There’
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For MM+M - Medical Marketing and Media, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.